STOCK TITAN

Staar Surgical Co. - STAA STOCK NEWS

Welcome to our dedicated news page for Staar Surgical Co. (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surgical Co..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Staar Surgical Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Staar Surgical Co.'s position in the market.

Rhea-AI Summary
STAAR Surgical Company (STAA) to Participate in Stephens Annual Investment Conference on November 16, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
conferences
-
Rhea-AI Summary
STAAR Surgical Company reported net sales of $80.3 million for the third quarter of 2023, a 6% increase compared to the prior year quarter. ICL sales were $81.1 million, up 13% year over year. Gross margin was 79.2%. Net income was $0.10 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.87%
Tags
-
Rhea-AI Summary
STAAR Surgical Company to release Q3 2023 financial results and host conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
conferences earnings
Rhea-AI Summary
STAAR Surgical Company celebrates the 30th anniversary of its Implantable Collamer Lens (ICL)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
none
-
Rhea-AI Summary
STAAR Surgical announces partnership with Jimmy O. Yang for EVO ICL lenses
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
partnership
-
Rhea-AI Summary
STAAR Surgical Company holds Vision 2026 investor day and celebrates 40th anniversary of being listed as a public company
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
none
Rhea-AI Summary
STAAR Surgical Company to host Investor Day on September 14, 2023 in New York City.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.06%
Tags
conferences
-
Rhea-AI Summary
STAAR Surgical Company (NASDAQ: STAA) announced a partnership with Tennessee Titans quarterback Will Levis to raise awareness of the FDA-approved EVO Implantable Collamer® Lenses for vision correction. The EVO ICL provides clear vision day or night, without causing dry eye syndrome, and is successful in correcting myopia and myopia with astigmatism. Levis will share his experience with EVO to drive education and awareness among millions of Americans suffering from myopia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
none
-
Rhea-AI Summary
STAAR Surgical Company announced its participation in several upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
conferences
Rhea-AI Summary
STAAR Surgical Company (NASDAQ: STAA) reported financial results for Q2 2023. Net sales were $92.3 million, up 14% YoY. Record ICL sales reached $93.1 million, up 19% YoY. Gross margin was 76.6%, down from 78.8% in the prior year quarter. Net income was $0.12 per share, compared to $0.26 per share in the prior year quarter. Cash, cash equivalents, and investments totaled $209.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.6%
Tags
Staar Surgical Co.

Nasdaq:STAA

STAA Rankings

STAA Stock Data

2.43B
37.60M
0.78%
107.7%
10.79%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Lake Forest

About STAA

staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl"​. nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad